Giant cell arteritis (GCA) is an autoimmune condition that causes the inflammation of large and medium sized blood vessels. An alternative name for this condition is “Temporal Arteritis” as the blood vessels in the temple area of the head (sides of the forehead) are commonly affected. The “giant” cells are abnormal large cells that develop in the wall of the inflamed arteries. GCA is very rare in people younger than 50 years, and is more common in women and people of northern European descent. The cause of GCA is not known. The most common symptoms of GCA include headache, with severe pain and tenderness over the temples and the scalp, prominent blood vessels at the temples, and pain in the jaw or tongue when talking or chewing. Visual loss occurs in up to 20% of patients, and this may be related to late recognition.
Tocilizumab is a disease modifying drug that acts by blocking specific proteins that signal the inflammatory processes affecting blood vessels in GCA. It is currently licensed for the treatment of GCA in adults as a subcutaneous (under the skin) injection, but reactions at the place of injection include redness, itching and pain. It is anticipated that these reactions would be avoided if the drug was given as an intravenous infusion.
AR101 is a form of treatment for peanut allergy. This treatment is administered orally with the aim of reeducatingthe body’s immune system, in order to increase the level at which the body reacts to peanuts, or toreduce the allergic response. The drug is targeted at adults and children with severe peanut allergy.Phase III clinical trials …